• Capricor Therapeutics (CAPR) Raised to Buy at Zacks Investment Research

    Capricor Therapeutics logo Capricor Therapeutics (NASDAQ:CAPR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday. The brokerage currently has a $2.00 price target on the biotechnology company’s stock. Zacks Investment …

    Read More
  • 0 0